120
Participants
Start Date
January 31, 2005
Primary Completion Date
December 31, 2006
Study Completion Date
December 31, 2006
Cetuximab + platinum + gemcitabine
Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
Platinum + Gemcitabine
Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
Local Institution, Mobile
Local Institution, Anchorage
Local Institution, Bakersfield
Local Institution, Corona
Local Institution, Oxnard
Local Institution, San Diego
Local Institution, Whittier
Local Institution, Lakewood
Local Institution, Boynton Beach
Local Institution, Brooksville
Local Institution, Inverness
Local Institution, Pembroke Pines
Local Institution, Austell
Local Institution, Honolulu
Local Institution, Skokie
Local Institution, Muncie
Local Institution, Annapolis
Local Institution, Frederick
Local Institution, Rockville
Local Institution, Plymouth
Local Institution, Farmington
Local Institution, Armonk
Local Institution, Stony Brook
Local Institution, Gastonia
Local Institution, Wilmington
Local Institution, Bismarck
Local Institution, Cincinnati
Local Institution, Portland
Local Institution, Charleston
Local Institution, Dallas
Local Institution, Vancouver
Local Institution, Edmonton
Local Institution, Moncton
Local Institution, Hamilton
Local Institution, Montreal
Local Institution, Toronto
Local Institution, Windsor
Local Institution, Greenfield Park
Eli Lilly and Company
INDUSTRY